84.42
+7.46%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About CareDx
From its filings with the US Securities and Exchange Commission
CareDx is based in Brisbane, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CDNA. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $379.8m and a net loss of $21.4m. At that date it held total assets of $413.2m and shareholders' equity of $303.1m. By business, Testing services revenue brought in 72.3% of revenue, followed by Patient and digital solutions revenue at 15.0% and Product revenue at 12.7%. By region, United States accounted for 94.8%, followed by Rest of World at 5.2%.
CareDx is a precision medicine company dedicated to improving outcomes for transplant patients and advancing organ health. We deliver solutions designed to empower clinicians and improve patient outcomes. The Company's integrated solutions include non-invasive molecular testing for heart, kidney, and lung transplants; laboratory products; digital health technologies; and patient solutions that support care before and after transplant. CareDx is the leading provider of genomics-based information for transplant patients. Our headquarters is located in Brisbane, California, and we have other primary operations in Omaha, Nebraska and Stockholm, Sweden.
We were originally incorporated in Delaware in December 1998 under the name Hippocratic Engineering, Inc. In April 1999, we changed our name to BioCardia, Inc., and in June 2002, we changed our name to Expression Diagnostics, Inc. In July 2007, we changed our name to XDx, Inc. and in March 2014, we changed our name to CareDx, Inc. Our principal executive offices are located at 8000 Marina Boulevard, Brisbane, California and our telephone number is (415) 287-2300. As of December 31, 2025, substantially all of our revenues came from the United States and Europe, and substantially all of our assets and operations were located in the United States and Sweden.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 Jul 2014
- Employees
- 761
- Website
- caredx.com ↗
- Head office
- 8000 MARINA BLVD, BRISBANE, CA, 94005
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Michael GoldbergIndependent Chairman of the Board, since 2011$743,374
- Mr. John HannaPresident, Chief Executive Officer, Director, since 2024$9.4m
- Mr. Nathan SmithChief Financial Officer
- Mr. Keith KennedyChief Operating Officer$4.5m
- Mr. Jeffrey NovackGeneral Counsel, Secretary$1.3m
- Ms. Jennifer FoleyChief Product Officer
- Ms. Jessica MengChief Commercial Officer$3.4m
- Mr. George BickerstaffIndependent Director$366,060
- Dr. Frederick CohenIndependent Director$353,437
- Ms. Christine CournoyerIndependent Director$372,303
- Mr. William HagstromIndependent Director$357,070
- Dr. Peter MaagIndependent Director, since 2012$350,030
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 82
- Environment
- 83
- Social
- 97
- Governance
- 64
- Direct emissions (scope 1)
- 1,080.02 t
- Energy emissions (scope 2)
- 525 t
- Women in the workforce
- 58%
- Carbon reduction policy
- Yes
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CareDx Inc is a leader in the field of transplant diagnostics, providing innovative solutions for organ transplant patients and healthcare professionals. The company has established a strong reputation for its high-quality products and services.
- CareDx Inc has a diverse and experienced team of professionals who possess deep knowledge and expertise in transplant medicine, molecular diagnostics, and bioinformatics. This allows the company to develop advanced diagnostic tools and technologies that meet the specific needs of transplant patients.
- The company's product portfolio includes a range of diagnostic tests that help assess the risk of rejection in organ transplant recipients, monitor post-transplant health, and guide personalized treatment decisions. These tests have the potential to improve patient outcomes and reduce healthcare costs.
- CareDx Inc has established strong relationships with transplant centers, hospitals, and clinics worldwide, providing them with reliable diagnostic solutions and support. This widespread adoption of the company's products contributes to its continued growth and market leadership.
Weaknesses
- As a specialized company focused on transplant diagnostics, CareDx Inc may be vulnerable to changes in regulations or reimbursement policies that affect the transplant industry. These regulatory uncertainties can impact the demand and usage of the company's products.
- The company's reliance on a limited number of key customers, such as transplant centers, may pose a risk to its business. Any significant loss of these key customers could have a negative impact on CareDx Inc's revenue and market share.
- CareDx Inc's heavy investment in research and development (R&D) to develop innovative products and technologies may result in increased expenses and financial risks. The success and commercialization of these R&D efforts are not guaranteed, and any setbacks could adversely affect the company's financial performance.
Opportunities
- The increasing demand for transplant procedures, driven by the growing prevalence of organ failure and advancements in transplantation techniques, presents opportunities for CareDx Inc to expand its customer base and revenue. The company can capitalize on this trend by enhancing its diagnostic capabilities and continuously developing new solutions.
- Expanding into emerging markets, where transplant diagnostics may be underdeveloped, can be a strategic opportunity for CareDx Inc. By establishing partnerships or alliances with local healthcare providers, the company can introduce its products and services to a wider audience and gain a competitive edge.
- The advancements in genomics and personalized medicine offer the potential for CareDx Inc to further tailor its diagnostic tools and provide personalized transplant solutions. By leveraging these technologies, the company can enhance patient care and differentiate itself from competitors.
Threats
- Competition from other companies operating in the transplant diagnostics market poses a threat to CareDx Inc's market share. These competitors may offer similar products or develop alternative diagnostic technologies that could disrupt the market and capture a portion of CareDx Inc's customer base.
- Changes in healthcare policies and insurance coverage can impact the demand for CareDx Inc's products. Reduced reimbursement rates or limitations in coverage for transplant diagnostics could affect the company's ability to generate revenue and maintain profitability.
- The unpredictable nature of organ availability and the success of transplant procedures can also pose a threat to CareDx Inc. If the number of transplant procedures declines or if organ rejection rates decrease significantly, the demand for the company's diagnostic tests may be affected.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.